BioWorld4h
In muscular dystrophies, gene therapies race the clock
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular diseases that can be evident from the ...
BioWorld1d
Former FDA chief Hamburg notes ‘challenging’ times post-Trump win
Former U.S. FDA Commissioner Margaret Hamburg has added her voice to concerns that the incoming Trump administration’s pledge ...
BioWorld2d
Ultromics’ AI software for cardiac amyloidosis gets FDA approval
Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...
BioWorld4d
Medtronic, Tempus ALERT to disparities in valve replacement
Medtronic plc and Tempus AI Inc. launched the ALERT study to better understand and address the racial, ethnic, gender and ...
BioWorld3d
Researchers develop first SDMA-based biosensor for kidney disease
Researchers developed a novel electrochemical biosensor technology capable of assessing symmetric dimethylarginine to detect early kidney disease, which could be adapted to detect other biomarkers for ...
BioWorld3d
Transposon Therapeutics acquires nucleoside analogues for cancer from Primefour
Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...
BioWorld3d
Asahi Kasei Pharma licenses rights to Chiome’s humanized anti-CX3CR1 antibody
Chiome Bioscience Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement to develop and commercialize Chiome’s humanized anti-CX3CR1 antibody, PFKR, currently in the ...
BioWorld3d
Two Stelara biosimilars among 15 US FDA approvals in October
The U.S. FDA approved 15 drugs in October, marking a decline from 24 in September and 22 in August. Despite the drop, the 2024 monthly average stands at about 19 approvals, exceeding last year’s ...
BioWorld3d
Telomir reports findings with Telomir-1 in aging model
Telomir Pharmaceuticals Inc. has reported preclinical results from evaluation of Telomir-1 in Caenorhabditis elegans, a well-established model for aging studies. Telomir-1 is a novel small molecule ...
BioWorld3d
Seed funding at Autoimmunity Biosolutions to advance immuno-corrective therapy for autoimmune diseases
Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...
BioWorld6d
Freya adds $11.8M for microbial immunotherapies in women’s health
Vaginal microbiome specialist Freya Bioscience ApS has added $11.8 million to its series A, bringing the total for the round ...
BioWorld3d
Pep2tango Therapeutics advances tetra-agonists for obesity
Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors ...